Limited Competition for the Continuation of HiLo: Pragmatic Trial of Higher versus Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis Clinical Centers (UH3- Clinical Trial Required)
The summary for the Limited Competition for the Continuation of HiLo: Pragmatic Trial of Higher versus Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis Clinical Centers (UH3- Clinical Trial Required) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition for the Continuation of HiLo: Pragmatic Trial of Higher versus Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis Clinical Centers (UH3- Clinical Trial Required): This Funding Opportunity Announcement (FOA) invites a renewal application from UH3 DK118748 supported by RFA-RM-16-019. This FOA will support the continuation and completion of HiLo: A pragmatic trial of higher vs lower serum phosphate targets in patients undergoing hemodialysis. The awardee will continue to enroll and follow hemodialysis patients in the HiLo trial to its completion.
Federal Grant Title: | Limited Competition for the Continuation of HiLo: Pragmatic Trial of Higher versus Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis Clinical Centers (UH3- Clinical Trial Required) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Food and Nutrition Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DK-22-501 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.847 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | October 19th, 2022 |
Original Application Deadline: | October 19th, 2022 |
Posted Date: | June 8th, 2022 |
Creation Date: | June 8th, 2022 |
Archive Date: | November 24th, 2022 |
Total Program Funding: | |
Maximum Federal Grant Award: | $1,000,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | June 9th, 2022 |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See Full Announcement for additional information on eligibility
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-501.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. - Similar Government Grants
- • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
- • Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
- • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
- • Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial...
- • Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial...
- • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes
- • Molecular Therapy Core Centers
- • Pilot and Feasibility Program in Human Islet Biology
- More Grants from the National Institutes of Health
- • Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Tr...
- • NINDS Research Education Opportunities (R25 Clinical Trial Not Allowed)
- • ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/U...
- • ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center (UG3/U...
- • Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01...